One of the problems currently faced in the management of SARS-CoV2
infection is the absence of specific treatments that have proven their
usefulness and their safety in studies with statistical validity, which
allows to justify on reasoned evidence its use. In the case of
paediatric patients although there are no serious cases in proportion to
adults, there is the ethical limitation of not having reliable data to
be able to justify therapeutic interventions on scientific evidence and
to date there are few studies that analyze the safety of certain drugs
and have not been included in paediatric groups in the evaluation of the
use of COVID-19 vaccines.